Author/Authors :
Goodarzi, Parisa Spinal Cord Injury Research Center - Tehran University of Medical Sciences - School of Nursing and Midwifery - Iran University of Medical Sciences, Tehran, Iran , Aghayan, Hamid Reza Chronic Diseases Research Center - Endocrinology and Metabolism Research Institute & Brain and Spinal Cord Injury Research Center - Tehran University of Medical Sciences, Tehran, Iran , Larijani, Bagher Metabolism Research Center - Endocrinology and Metabolism Research Institute - Tehran University of Medical sciences, Tehran, Iran , Soleimani, Masoud Hematology Department - Faculty of Medicine - Tarbiat Modares University, Tehran, Iran , Dehpour, Ahmad-Reza School of Medicine - Tehran University of Medical Sciences, Tehran, Iran , Sahebjam, Mehrnaz Brain and Spinal Cord Injury Research Center - Tehran University of Medical Sciences, Tehran, Iran , Ghaderi, Firoozeh Brain and Spinal Cord Injury Research Center - Tehran University of Medical Sciences, Tehran, Iran , Arjmand, Babak GMP-Compliant Stem Cell Facility - Endocrinology and Metabolism Research Center - Endocrinology and Metabolism Research Institute & Brain and Spinal Cord Injury Research Center - Tehran University of Medical Sciences - Shariati Hospital - North Kargar, Tehran, Iran
Abstract :
Parkinson’s disease (PD) is the second most common neurodegenerative brain disorder which is around 1.5
times more common in men than in women. Currently, drug medications, surgery, and lifestyle changes are
common approaches to PD, while all of them focused on reducing the symptoms. Therefore, regenerative medicine
based on stem cell (SC) therapies has raised a promising hope. Various types of SCs have been used in
basic and experimental studies relevant to PD, including embryonic pluripotential stem cells, mesenchymal
(MSCs) and induced pluripotent SCs (iPSCs). MSCs have several advantages over other counterparts. They are
easily accessible which can be obtained from various tissues such as bone marrow, adipose tissue, peripheral
blood, etc. with avoiding ethical problems. Therefore, MSCs is attractive clinically because there are no related
ethical and immunological concerns . Further studies are needed to answer some crucial questions about the
different issues in SC therapy. Accordingly, SC-based therapy for PD also needed more complementary evaluation
in both basic and clinical study areas.
Keywords :
Stem cell , Parkinson’s disease , Neurodegenerative diseases , Cellular therapy
